Rating Change
Morgan Stanley reiterated its Underweight rating on Bristol-Myers Squibb Company (NYSE:BMY) on October 07, 2026.
reiterateNYSE:BMY
Morgan Stanley Reiterates Underweight Rating on Bristol-Myers Squibb Company (BMY)
Morgan Stanley reiterated its Underweight rating on Bristol-Myers Squibb Company (NYSE:BMY) on October 07, 2026.
At publication ·
What changed
Bristol-Myers Squibb Company (NYSE:BMY) · reiterate
- Firm
- Morgan Stanley
- Rating
- Underweight to Underweight
- Price at event
- $59.70
- Market capitalization
- $104.2B
At a glance
Key takeaways
- Morgan Stanley reiterated an Underweight rating on Bristol-Myers Squibb on October 7, 2026, suggesting the stock may underperform.
Market Context
Bristol-Myers Squibb Company operates in the Healthcare sector. The stock currently trades at $59.70 with a market capitalization of $104.2B. The stock has gained 9.0% over the past 52 weeks.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Bristol-Myers Squibb Company.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Bristol-Myers Squibb Company
Among the 10 most recent ratings: 4 Buy, 5 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 07, 2026 | Morgan Stanley | Underweight | N/A |
| Oct 05, 2026 | Leerink Partners | Market Perform | N/A |
| Sep 16, 2026 | Piper Sandler | Overweight | N/A |
| Sep 10, 2026 | HSBC | Hold | N/A |
| Aug 05, 2026 | Argus Research | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View BMY Stock Page
Frequently Asked Questions
What does the Underweight rating mean for BMY?
A rating of Underweight from Morgan Stanley reflects the analyst's outlook on Bristol-Myers Squibb Company (NYSE:BMY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BMY forecast page.
